Amplifying The Vaccines Of Tomorrow
AdJane is advancing next-generation vaccines and adjuvants to combat critical global health challenges. Our OMV-Vacc platform technology will redefine vaccine development.
About Us
At AdJane, we believe our OMV-Vacc platform technology will redefine vaccine development. Harnessing the natural power of Outer Membrane Vesicles (OMVs), we target diseases with highly unmet medical needs through our innovative vaccines and novel adjuvants. As a female-led company, we’re setting a new precedent in biotech beyond scientific innovation.
AdJane was founded to fill a critical gap in the vaccine landscape: the need for safer, broadly protective, and efficient vaccines that do not rely on traditional aluminum adjuvants. Built around our novel OMV-Vacc platform, AdJane is advancing next-generation vaccines and adjuvants to combat critical global health challenges.
OMV-Vacc
Our proprietary vaccine platform technology
Outer Membrane Vesicles (OMVs) are naturally released spherical nanoparticles by gram-negative bacteria. These non-replicating vesicles carry strong immune potentiators such as PAMPs and trigger an immune response, enabling protective immunity.
Timelines & Milestones
Combatting Antimicrobial Resistance and Neglected Disease
Our OMV technology has demonstrated an excellent safety profile in phase I clinical trials, is administration-route-agnostic, scalable, and stable over years. See our diversified pipeline of high impact programs for more information.
ADA
Our own adjuvants, ADA-24 and ADA-25, based on its proprietary OMV-Vacc platform technology. Status: phase I concluded with positive results.
BEA
A Gonorrhea vaccine based on its proprietary OMV-Vacc platform technology. OMV-Vacc platform technology. Status: Commencing on 2 challenge studies and tox. batch manufacturing
CARA
A next-generation multivalent HFMD vaccine that offers broad protection against four distinct strains. Status: Commencing tox. batch manufacturing